Cartesian Therapeutics, Inc.

What they do

Cartesian Therapeutics is a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases using mRNA technology. The company's proprietary platform introduces mRNA into cells to provide therapeutic effects, designed for repeated outpatient dosing without preconditioning chemotherapy. Its most advanced product candidate, Descartes-08, is an autologous anti-BCMA CAR-T therapy in Phase 3 development for myasthenia gravis (MG), with additional programs in myositis and juvenile dermatomyositis.

Revenue drivers

• Collaboration and license revenue — Revenue from upfront and milestone payments under collaboration and license agreements, including a recent partnership with WestGene BioPharma.
• Grant revenue — Funding received for specific research and development services under grant arrangements.
• No product sales — The company has no approved products and has not generated any product sales; revenue is expected to fluctuate with collaboration and grant timing.

Recent performance

For the six months ended June 30, 2026, Cartesian incurred a net loss of $23.4 million, compared to a net loss of $1.8 million in the same period of 2025. As of June 30, 2026, the company had cash, cash equivalents, and restricted cash of approximately $149.3 million. Accumulated deficit was $845.8 million. Quarterly revenue for the last four quarters (ending June 30, 2026) was $0.00.

Strategy

Management's stated priorities include advancing Descartes-08 through Phase 3 development in MG, with a BLA filing planned for mid-2027. The company is also advancing Descartes-08 into Phase 2 for myositis and Phase 1/2 in juvenile dermatomyositis. A new licensing agreement with WestGene aims to accelerate an in vivo CAR-T platform, potentially eliminating ex vivo manufacturing. The company secured a non-dilutive credit facility with K2 HealthVentures of up to $150 million to extend cash runway into 2028.

Risks

• Unproven approach — The mRNA-based cell therapy platform is unproven for autoimmune disease and may fail in clinical trials or regulatory approval.
• No approved products — Cartesian has no products approved for sale, no product revenue, and expects continued losses for the foreseeable future.
• Negative equity — As of June 30, 2026, shareholder equity was negative at $-125.2 million, with total liabilities of $443.9 million.
• Dependence on collaborators — The company relies on third-party collaborators, CROs, and contract manufacturing organizations, and failure to perform could delay or halt development.

Outlook

Management expects data from several clinical trials over the next twelve months: Phase 3 AURORA (MG) data in 1Q27, Phase 2 TRITON (myositis) subset data in 1H27, Phase 1/2 HELIOS (juvenile dermatomyositis) data in 1H27, and Phase 1 in vivo trial data (with WestGene) in 1H27. BLA filing for Descartes-08 is planned for mid-2027. Based on current cash, the company expects to fund operations into 2028.